These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15711245)

  • 1. Is benign prostatic hyperplasia a risk factor for chronic renal failure?
    Rule AD; Lieber MM; Jacobsen SJ
    J Urol; 2005 Mar; 173(3):691-6. PubMed ID: 15711245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
    Parsons JK
    J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gerber GS; Goldfischer ER; Karrison TG; Bales GT
    Urology; 1997 May; 49(5):697-702. PubMed ID: 9145973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia.
    Rosen RC
    Curr Opin Urol; 2006 Jan; 16(1):11-9. PubMed ID: 16385195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia.
    Burke JP; Rhodes T; Jacobson DJ; McGree ME; Roberts RO; Girman CJ; Lieber MM; Jacobsen SJ
    Am J Epidemiol; 2006 Jul; 164(1):41-6. PubMed ID: 16611664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know?
    Sarma AV; Parsons JK; McVary K; Wei JT
    J Urol; 2009 Dec; 182(6 Suppl):S32-7. PubMed ID: 19846144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention.
    Ghalayini IF; Al-Ghazo MA; Pickard RS
    BJU Int; 2005 Jul; 96(1):93-7. PubMed ID: 15963128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition of at-risk patients: baseline variables.
    Roehrborn CG
    BJU Int; 2006 Apr; 97 Suppl 2():7-11; discussion 21-2. PubMed ID: 16507046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Kaplan SA; Walmsley K; Te AE
    J Urol; 2005 Dec; 174(6):2273-5. discussion 2275-6. PubMed ID: 16280803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benign prostatic hyperplasia presenting with renal failure--what is the role for transurethral resection of the prostate (TURP)?
    Thomas AZ; Thomas AA; Conlon P; Hickey D; Little DM
    Ir Med J; 2009 Feb; 102(2):43-4. PubMed ID: 19405316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary retention and post-void residual urine in men: separating truth from tradition.
    Kaplan SA; Wein AJ; Staskin DR; Roehrborn CG; Steers WD
    J Urol; 2008 Jul; 180(1):47-54. PubMed ID: 18485378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria and renal function during and after acute urinary retention.
    Mustonen S; Ala-Houhala I; Tammela TL
    J Urol; 1999 Jun; 161(6):1781-4; discussion 1784-5. PubMed ID: 10332434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.